Hierarchical porous bioactive glasses/PLGA-magnetic SBA-15 for dual-drug release

Engineering mesoporous bioactive glasses for emerging stimuli-responsive drug delivery and theranostic applications

Mesoporous bioactive glasses (MBGs), which belong to the category of modern porous nanomaterials, have garnered significant attention due to their impressive biological activities, appealing physicochemical properties, and desirable morphological features. They hold immense potential for utilization in diverse fields, including adsorption, separation, catalysis, bioengineering, and medicine. Despite possessing interior porous structures, excellent morphological characteristics, and superior biocompatibility, primitive MBGs face challenges related to weak encapsulation efficiency, drug loading, and mechanical strength when applied in biomedical fields. It is important to note that the advantageous attributes of MBGs can be effectively preserved by incorporating supramolecular assemblies, miscellaneous metal species, and their conjugates into the material surfaces or intrinsic mesoporous networks. The innovative advancements in these modified colloidal inorganic nanocarriers inspire researchers to explore novel applications, such as stimuli-responsive drug delivery, with exceptional in-vivo performances. In view of the above, we outline the fabrication process of calcium-silicon-phosphorus based MBGs, followed by discussions on their significant progress in various engineered strategies involving surface functionalization, nanostructures, and network modification. Furthermore, we emphasize the recent advancements in the textural and physicochemical properties of MBGs, along with their theranostic potentials in multiple cancerous and non-cancerous diseases. Lastly, we recapitulate compelling viewpoints, with specific considerations given from bench to bedside.

Antibacterial and pro-osteogenic effects of β-Defensin-2-loaded mesoporous bioglass

The human antimicrobial peptide beta-defensin-2 (hBD2) shows broad antibacterial activity and infrequent bacterial resistance. Here mesoporous bioactive glass (MBG) was loaded with hBD2, forming hBD2-loaded MBG (BD-MBG). The antibacterial and osteogenic effects of BD-MBG were investigated in comparison with MBG and the blank control (BC). The result showed that BD-MBG yielded sustained hBD2 release for more than 7 weeks in vitro, and resulted in significantly lower amounts of viable bacteria and colony forming units, and significantly higher levels of bacterial protein release compared with those in the BC and MBG groups (all p<0.05). Compared with that in the BC group, significantly higher bone marrow stromal cell (BMSC) proliferation rates, alkaline phosphatase (ALP) activity, calcium nodule formation, and expression levels of early and late osteogenic makers were observed after MBG and BD-MBG treatments (p<0.05). Thus, BD-MBG inhibited bacterial growth, damaged their membrane, and promoted early and late osteogenic BMSC differentiation.

Biomimetic Composite Scaffold Containing Small Intestinal Submucosa and Mesoporous Bioactive Glass Exhibits High Osteogenic and Angiogenic Capacity

Biomaterials with excellent osteogenic and angiogenic activities are desirable to repair massive bone defects. Decellularized matrix from porcine small intestinal submucosa (SIS) has attracted particular attention for tissue regeneration because it has strong angiogenic effects and retains plentiful bioactive components. However, it has inferior osteoinductivity and osteoconductivity. In this study, we developed porous composite of SIS combined with mesoporous bioactive glass (SIS/MBG) with the goal of improving the mechanical and biological properties. SIS/MBG scaffolds showed uniform interconnected macropores (∼150 μm), high porosity (∼76%), and enhanced compressive strength (∼0.87 MPa). The proliferation and osteogenic gene expression (Runx2, ALP, Ocn, and Col-Iα) of rat bone marrow stromal cells (rBMSCs) as well as the proliferation, angiogenic gene expression (VEGF, bFGF, and KDR), and tube formation capacity of human umbilical vein endothelial cells (HUVECs) in SIS/MBG scaffolds were significantly upregulated compared with nonmesoporous bioactive glass (BG)-modified SIS (SIS/BG) and SIS-only scaffolds. Western blot analysis revealed that SIS/MBG induced rBMSCs to osteogenic differentiation through the activation of Wnt/β-Catenin signaling pathway, and SIS/MBG enhanced angiogenic activity of HUVEC through the activation of PI3k/Akt pathways. The in vivo results demonstrated that SIS/MBG scaffolds significantly enhanced new bone formation and neovascularization simultaneously in critical-sized rat calvarial defects as compared with SIS/BG and SIS. Collectively, the osteostimulative and angiostimulative biomimetic composite scaffold SIS/MBG represents an exciting biomaterial option for bone regeneration.

Function and mechanism of mesoporous bioactive glass adsorbed epidermal growth factor for accelerating bone tissue regeneration

Mesoporous bioactive glass (MBG) has been demonstrated to play a vital role in bone tissue engineering due to its bioactivity, biocompatibility, and osteoinduction properties. Here, we report that MBG grafted with an amino group (MBG-NH₂) and MBG-NH₂ adsorbed epidermal growth factor (EGF) (MBG-NH₂/EGF) sustained-release EGF, and MBG-NH2/EGF could accelerate osteoblast differentiation and mineralization in MC3T3-E1 cells. We found that MBG-NH₂ could promote bone-like deposit formation and Ca deposition in vitro. Intriguingly, we observed that MBG-NH₂/EGF enhanced MC3T3-E1 cell adhesion. We also showed that extracellular signal-regulated kinase 1/2 (ERK1/2) was phosphorylated when MC3T3-E1 cells were cultured on MBG-NH₂/EGF. Interestingly, the transcription factor Runx2, important for osteoblast differentiation, was also activated when MC3T3-E1 cells were cultured on MBG-NH₂/EGF. We showed that MC3T3-E1 cells cultured on MBG-NH₂/EGF activating Runx2 was through ERK1/2 phosphorylation. Consistent with this survey, we observed that MC3T3-E1 cells cultured on MBG-NH₂/EGF accelerated osteoblastic marker gene expressions, including osteopontin (Opn) and osteocalcin (Ocn). Taken together, we conclude that the osteoblast differentiation and mineralization were accelerated in MC3T3-E1 cells cultured on MBG-NH₂/EGF through ERK-activated Runx2 pathway. These findings support the idea that MBG-NH₂/EGF is a potential biomaterial for bone tissue repair in bone defect-related diseases.

Composite Biomaterials Based on Sol-Gel Mesoporous Silicate Glasses: A Review

Bioactive glasses are able to bond to bone and stimulate the growth of new tissue while dissolving over time, which makes them ideal materials for regenerative medicine. The advent of mesoporous glasses, which are typically synthesized via sol-gel routes, allowed researchers to develop a broad and versatile class of novel biomaterials that combine superior bone regenerative potential (compared to traditional melt-derived glasses) with the ability of incorporating drugs and various biomolecules for targeted therapy in situ. Mesoporous glass particles can be directly embedded as a bioactive phase within a non-porous (e.g., microspheres), porous (3D scaffolds) or injectable matrix, or be processed to manufacture a surface coating on inorganic or organic (macro)porous substrates, thereby obtaining hierarchical structures with multiscale porosity. This review provides a picture of composite systems and coatings based on mesoporous glasses and highlights the challenges for the future, including the great potential of inorganic-organic hybrid sol-gel biomaterials.

Bioactive glass-based materials with hierarchical porosity for medical applications: Review of recent advances

Bioactive glasses have been traditionally used in the clinical practice to fill and restore osseous defects due to their unique ability to bond to host bone and stimulate new bone growth. In the last decade, a new set of bioactive glasses characterized by a highly ordered mesoporous texture has been developed and studied as a smart platform for the controlled release of biomolecules, in situ therapy and regenerative applications. This review points out the great potential carried by hierarchical bioactive glass scaffolds that exhibit pore scales from the meso- to the macro-range, and their impact in the broad field of tissue engineering, including the emerging applications in contact with soft tissues and diagnostics. Recent advances in the preparation methods of these multiscale constructs (e.g. mono- or multi-phase scaffolds, fibrous meshes, coated systems, porous nanospheres, and composites) are examined, along with their strengths and weaknesses. A bright future is expected for hierarchical systems based on biocompatible mesoporous materials as they can provide a unique set of functionalities, including enhanced bioactivity, local release of ions and drugs to elicit specific therapeutic effects (improved osteogenesis and angiogenesis, antibacterial properties), and implant/drug tracking, which were unthinkable when research on bioactive glasses began.

STATEMENT OF SIGNIFICANCE

The advent of mesoporous bioactive glasses led to the birth of a new class of multifunctional biomaterials that have been proposed as smart platforms for local drug release and bone regeneration. Furthermore, mesoporous materials have been recently employed in the development of hierarchical macro-mesoporous scaffolds, composites and implantable systems. This reviews summarizes the latest applications of these multiscale biomaterials in tissue engineering, including the emerging applications in contact with soft tissues and diagnostics. The preparation methods, current uses and potential of these constructs and systems are examined and critically discussed to provide a useful, up-to-date contribution to the scientists working in the field.

Development of a novel CsA-PLGA drug delivery system based on a glaucoma drainage device for the prevention of postoperative fibrosis

The formation of a scar after glaucoma surgery often leads to unsuccessful control of intraocular pressure, and should be prevented by using a variety of methods. We designed and developed a novel drug delivery system (DDS) comprising cyclosporine A (CsA) and poly(lactic-co-glycolic acid) (PLGA) based on a glaucoma drainage device (GDD) that can continuously release CsA to prevent postoperative fibrosis following glaucoma surgery. The CsA@PLGA@GDD DDS was observed by field emission scanning electron microscopy and revealed an asymmetric pore structure. Thermogravimetric analysis was performed to measure the weight loss and evaluate the thermal stability of the CsA@PLGA@GDD DDS. The in vitro drug release profile of the DDS was studied using high performance liquid chromatography, which confirmed that the DDS released CsA at a stable rate and maintained adequate CsA concentrations for a relatively long time. The biocompatibility of the DDS and the inhibitory effects on the postoperative fibrosis were investigated in vitro using rabbit Tenon's fibroblasts. The in vivo safety and efficacy of the DDS were examined by implanting the DDS into Tenon's capsules in New Zealand rabbits. Bleb morphology, intraocular pressure, anterior chamber reactions, and anterior chamber angiography were studied at a series of set times. The DDS kept the filtration pathway unblocked for a longer time compared with the control GDD. The results indicate that the CsA@PLGA@GDD DDS represents a safe and effective strategy for preventing scar formation after glaucoma surgery.

Functionalized silica nanoparticles as a carrier for Betamethasone Sodium Phosphate: Drug release study and statistical optimization of drug loading by response surface method

Mesoporous silica nanoparticles with a hexagonal structure (SBA-15) were synthesized and modified with (3-aminopropyl) triethoxysilane (APTES), and their performance as a carrier for drug delivery system was studied. Chemical structure and morphology of the synthesized and modified SBA-15 were characterized by SEM, BET, TEM, FT-IR and CHN technique. Betamethasone Sodium Phosphate (BSP) as a water soluble drug was loaded on the mesoporous silica particle for the first time. The response surface method was employed to obtain the optimum conditions for the drug/silica nanoparticle preparation, by using Design-Expert software. The effect of time, pH of preparative media, and drug/silica ratio on the drug loading efficiency was investigated by the software. The maximum loading (33.69%) was achieved under optimized condition (pH: 1.8, time: 3.54 (h) and drug/silica ratio: 1.7). The in vitro release behavior of drug loaded particles under various pH values was evaluated. Finally, the release kinetic of the drug was investigated using the Higuchi and Korsmeyer-Peppas models. Cell culture and cytotoxicity assays revealed the synthesized product doesn't have any cytotoxicity against human bladder cell line 5637. Accordingly, the produced drug-loaded nanostructures can be applied via different routes, such as implantation and topical or oral administration.

The role of SBA-15 in drug delivery

In this review, preparation, characterization and application of various types of SBA-15 as drug delivery agents is investigated.

Evaluation of mesoporous SBA-15 for the controlled delivery of ciprofloxacin hydrochloride

Controlled drug release of ciprofloxacin hydrochloride monohydrate has been investigated by loading into the channels of SBA-15 mesoporous silica. Three categories of SBA-15 were prepared by a sol-gel process according to blank SBA-15, calcined SBA-15 and SBA-15 functionalised with 3-aminopropyltriethoxysilane (APTS) in a 1:1 ratio prior to drug loading. The carrier and drug samples were characterised by small-angle X-ray diffraction (SAXRD), N2 adsorption–desorption isotherm measurements, fourier transform infrared spectroscopy (FT-IR) and ultraviolet (UV) spectrophotometry. Controlled drug release was conducted in buffered neutral conditions at room temperature for 24, 48 and 120 h. Maximum desorption was observed in the case of the amino-functionalised SBA-15 after 120 h corresponding to 72·16%, whereas for calcined SBA-15 this amounted to 71·35% and in the case of blank SBA-15 48·34% of the total amount of loaded drug was liberated demonstrating the slow release effect of mesoporous silica.